Skip to content
PeptideFactSheets
Not FDA approvedEarly human evidence

Vitamin B3-related NAD+ precursor fact sheet

Nicotinamide riboside

Also known as NR, niagen

Healthy agingMitochondrial healthCognition and brainMetabolic health

Nicotinamide riboside is converted through cellular pathways toward NAD+. Human trials usually show biomarker changes, while clinical outcomes remain mixed or negative.

Quick answer

Nicotinamide riboside can raise NAD-related biomarkers in people, but it is not an FDA-approved drug for aging, cognitive decline, mitochondrial disease, or fatigue. Biomarker movement should not be confused with proven health benefit.

By the PeptideFactSheets Editorial Team. Use the source links to verify status, evidence, risks, and unknowns; our editorial policyexplains the boundaries. Clinician review appears only when a named reviewer is shown.

What is Nicotinamide riboside?

Nicotinamide riboside is a vitamin B3-related compound and one of several precursors cells can use to make NAD+.

It is sold in dietary supplements, a category FDA does not approve for safety and effectiveness before marketing.

Why are people interested in it?

NR offers an oral way to influence NAD metabolism without administering NAD+ itself.

It is studied across metabolic, cardiovascular, muscle, neurological, and aging-related questions, but small trials and multiple endpoints make isolated positive signals easy to overinterpret.

Current regulatory status

Not FDA approved

No nicotinamide-riboside drug is FDA approved to prevent or treat aging, cognitive decline, mitochondrial dysfunction, or fatigue. Dietary-supplement marketing does not equal FDA approval.

What is it approved for?

No FDA-approved use. Commercial availability, supplement marketing, and clinical research do not equal an FDA-approved medicine.

FDA approval path

No active FDA drug path

Supplement and food-ingredient status, not drug approval

Nicotinamide riboside has human biomarker trials and food-ingredient regulatory material, but no FDA-approved drug use for aging, cognition, fatigue, or disease treatment.

  1. DiscoveryBasic research
  2. PreclinicalLab and animal work
  3. Phase 1Initial human testing
  4. Phase 2Condition-focused trials
  5. Phase 3Confirmatory trials
  6. FDA reviewApplication review
  7. ApprovedLabel-specific use

This status sits outside the standard stepwise FDA drug-approval path.

Timeline source basis

FDA GRAS notice response materials for NR chlorideFDA: what ‘FDA approved’ does and does not meanSystematic review of NAD precursor trials

What is it being studied for?

NAD+ metabolism
Mild cognitive impairment
Cardiometabolic and vascular outcomes
Muscle and mitochondrial function

Evidence snapshot

Early human evidence

Multiple human trials establish absorption and biomarker effects. Controlled studies have not yet established a durable, reproducible benefit on cognition, physical function, or major clinical outcomes.

Potential benefits being researched

  • Trials commonly report increased blood NAD-related metabolites.
  • A randomized pilot in mild cognitive impairment found target engagement but did not show a significant cognitive benefit over placebo.

A mechanism, biomarker, or secondary endpoint is not proof of a meaningful clinical benefit.

Known or possible risks

  • Short controlled studies generally report acceptable tolerability, but they are not large or long enough to define uncommon harms.
  • Supplement strength, purity, and labeling can vary, and FDA does not preapprove supplements for effectiveness.
  • Long-term consequences of chronically altering NAD metabolism in diverse populations are uncertain.

What we still do not know

  • Whether any biomarker change improves healthspan or disease outcomes
  • Whether a specific deficient or disease-defined population benefits
  • Long-term safety and clinically meaningful interactions
  • How NR compares with NMN or lifestyle interventions on patient-centered outcomes

Plain-English takeaway

NR has credible human target-engagement data, but a higher NAD biomarker is a research result—not proof of better memory, energy, or longevity.

Research and reference links

Use these primary and authoritative sources to verify status and read beyond this summary. A study or registry entry does not by itself prove benefit.

  1. 1
    pubmedRandomized NR pilot in mild cognitive impairment

    Placebo-controlled pilot reporting biomarker engagement without a significant cognitive benefit.

  2. 2
    pubmedSystematic review of NAD precursor trials

    Review of human NR and NMN trials describing consistent biomarker effects and heterogeneous clinical outcomes.

  3. 3
    fdaFDA GRAS notice response materials for NR chloride

    Food-ingredient regulatory record; GRAS status is not approval of anti-aging or disease claims.

  4. 4
    fdaFDA: what ‘FDA approved’ does and does not mean

    FDA explains that dietary supplements are not approved for safety and effectiveness before marketing.